An AAM-sponsored study by researcher Avalere Health has concluded that Medicare Part D policy changes have led to generics being placed on non-generic tiers 53% of the time in 2020, with generics placed on the ‘preferred generic’ Tier 1 just 10% of the time.

French off-patent industry association Gemme has declared a “state of emergency” for French generics as it revealed industry data for 2019 pointing to weak growth. Meanwhile, Gemme says, the country’s biosimilars market is “dynamic” and growing quickly but is still under-performing.

Continuing UK price rises were seen for nefopam in January, according to the latest figures from market researcher WaveData.

On the eve of the UK’s formal exit from the EU on 31 January, BGMA director general Warwick Smith has insisted that it is essential for the UK to stay as close as possible to the current European medicines framework following the conclusion of a transition period that is currently due to expire at the end of 2020.

December brought price rises for the UK generics market that included imipramine prices as much as doubling and a leap of more than two-thirds in the average price of frovatriptan tablets.

Indian companies should post “healthy” growth in 2020, helped by a robust domestic market and abating US pricing pressures, analysts say.